Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 65 of 1,261
  1. US 12213996

    Methods of treating optic nerve diseases using neural progenitor cell growth factors

    REGENERATIVE RESEARCH FOUNDATION Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  2. US 12214015

    Use of c-type natriuretic peptide variants to treat osteoarthritis

    BIOMARIN PHARMACEUTICAL INC. Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  3. US 12213973

    Bacterial nitric oxide synthase inhibitors

    Northwestern University Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  4. US 12213989

    Use of maribavir in treatment regimens

    Takeda Pharmaceutical Company Limited Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  5. US 12214023

    Compositions and methods for expressing factor IX

    REGENERON PHARMACEUTICALS, INC. Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  6. US 12214021

    Study on lactoferrin regulation of bone formation by means of vitamin D receptor

    China Agricultural University Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  7. US 12214014

    Methods for scar reduction by converting scar fibroblasts into adipocytes with hair follicle-derived signals

    The Regents of the University of California Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  8. US 12214061

    Adhesive composition for dental use

    KURARAY NORITAKE DENTAL INC. Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  9. US 12215131

    IgG Fc-IL2-RΞ±-IL2 fusions and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  10. US 12215164

    Immunotoxins with albumin binding domain

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  11. US 12215138

    Compositions and methods for internalizing enzymes

    REGENERON PHARMACEUTICALS, INC. Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  12. US 12215105

    HPK1 antagonists and uses thereof

    Nimbus Saturn, Inc. Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  13. US 12219327

    Substituted isoindolines as PI3K-alpha inhibitors

    Relay Therapeutics, Inc. Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  14. US 12213985

    Oral cannabinoid formulations

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  15. US 12213998

    Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease

    Takeda Pharmaceutical Company Limited Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  16. US 12213977

    Methods and compositions for treating melanoma

    The Regents of the University of California Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  17. US 12214002

    Compositions and methods for treating antibiotic resistance

    Seres Therapeutics, Inc. Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  18. US 12213964

    Isoxazoline parasiticide formulations

    Tarsus Pharmaceuticals, Inc. Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  19. US 12213951

    Treatment of autism with cannabidiol

    Harmony Biosciences Management, Inc. Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  20. US 12214218

    Perfusion modulated tumor dose sculpting with single dose radiotherapy

    FUNDAΓ§ΓƒO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  21. US 12215343

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California Β· Granted Feb 4, 2025 Β· Expires Jan 30, 2045

    granted
  22. WO 2025023852

    ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE

    BIAL PORTELA & CA SA [PT] Β· Granted Jan 30, 2025 Β· Expires Jan 25, 2045

    granted
  23. WO 2025023851

    ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE

    BIAL PORTELA & CA SA [PT] Β· Granted Jan 30, 2025 Β· Expires Jan 25, 2045

    granted
  24. US 2025034157

    PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

    ABBVIE INC [US] Β· Granted Jan 30, 2025 Β· Expires Jan 25, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.